Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
South Korea’s leading biologics companies will invest hundreds of billions of won to building additional plants that would push the total amount of private investments for the biohealth industry to 10 trillion won by 2023.
Samsung Biologics will pour 1.7 trillion won into its new Plant 4 while Celltrion will invest 500 billion won to its Global Life Science Research Lab and Plant 3, all in Songdo, Incheon.
As its action plan for a more robust bio-industry ecosystem, the Government also pledged a 1.7 trillion won budget in 2021, up 30 percent from last year’s. The budget will prioritize pharmaceuticals, medical devices, and digital health care.
Biohealth players are building an ecosystem for biologics in Songdo, which now hosts 60 South Korean and international bio-related companies, employing around 7,000.
About 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms by 2023.
It would boost manufacturing capacity by 20 percent and employ an additional 9,300.
The government envisions the biologics workforce to grow to 47,000 by 2025 in a joint effort with the academe.
The regional bio clusters of Songdo, Wonju in Gangwon Province, Osong in North Chungcheong Province, and Daegu will increase collaboration.
The biologics industry is globally increasing 4 percent annually, higher than shipbuilders at 2.9 percent and car manufacturers at 1.5 percent.
